Doripenem 500mg InjectionInjection
Antibiotics

Doripenem 500mg Injection

Doripenem

Ultra-broad-spectrum carbapenem with enhanced stability against renal dehydropeptidase and potent activity against Pseudomonas aeruginosa, approved for complicated UTI and intra-abdominal infections. Manufactured by Cipla and Glenmark for ICU and hospital-based infection management in export markets.

Strengths

500mg

Packing

1 vial/box

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Doripenem 500mg lyophilized powder for infusion
Dosage Form
Injection
Available Strengths
500mg
Packing
1 vial/box
Route of Administration
Intravenous infusion over 1-4 hours
Dosage
500mg IV every 8 hours; infusion over 1 hour (standard) or 4 hours (extended for Pseudomonas)
Indications
Complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 25°C
Shelf Life
24 months
Side Effects
Headache, nausea, diarrhea, rash, phlebitis, oral candidiasis, elevated hepatic enzymes
Precautions
Seizure risk in CNS disorders; C. difficile associated diarrhea; dose adjustment for CrCl <50; not approved for nosocomial pneumonia (increased mortality in trial); cross-allergy with penicillins

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Azithromycin 500mgTablet

Azithromycin 500mg

Azithromycin

Azalide subclass macrolide antibiotic that achieves exceptionally high and sustained intracellular tissue concentrations — up to 100-fold higher than plasma levels — enabling short 3-day or 5-day treatment courses for respiratory, skin, and sexually transmitted bacterial infections. Its anti-inflammatory properties beyond direct bacteriostasis provide additional clinical benefit in community-acquired pneumonia. Cipla and Alkem Labs manufacture 250mg and 500mg tablets exported globally as a staple of primary care antibiotic formularies.

250mg / 500mg
Amoxicillin 500mgCapsule

Amoxicillin 500mg

Amoxicillin Trihydrate

Aminopenicillin with extended gram-positive and gram-negative bactericidal activity, offering superior oral bioavailability (~90%) compared to ampicillin and the convenience of twice- or thrice-daily dosing for common community infections of the respiratory tract, urinary tract, skin, and ear. It is also a key component of H. pylori triple-eradication therapy and is a WHO Essential Medicine available in both capsule and dispersible tablet forms. Cipla and GSK manufacture 250mg and 500mg capsules exported to primary care markets globally.

250mg / 500mg
Augmentin 625mgTablet

Augmentin 625mg

Amoxicillin + Clavulanate

Fixed-dose combination of amoxicillin with clavulanic acid, a potent beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation and restores its activity against beta-lactamase-producing strains of Staphylococcus, Haemophilus, Moraxella, and Klebsiella commonly encountered in community and hospital settings. Widely prescribed for sinusitis, otitis media, lower respiratory infections, UTIs, animal bites, and dental abscesses resistant to amoxicillin alone. GSK and Cipla supply 625mg and 1g tablets exported as a primary care antibiotic staple worldwide.

625mg / 1g

Need bulk pricing for Doripenem 500mg Injection?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote